Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

June 30, 2016

Conditions
Heart Failure
Interventions
DEVICE

HM II (HeartMate II LVAD)

The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.

DRUG

OMM (Optimal Medical Management)

Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.

Trial Locations (52)

10029

Mt. Sinai Medical Center, New York

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

12601

Hudson Valley Heart Center, Poughkeepsie

14642

University of Rochester Medical Center, Rochester

17033

Penn State Milton Hershey Medical Center, Hershey

19001

Abington Memorial Hospital, Abington

19104

Hospital of the University of Pennsylvania, Philadelphia

22042

Inova Fairfax Hospital, Falls Church

Virginia Heart, Falls Church

23298

Virginia Commonwealth University, Richmond

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

30322

Emory University Hospital, Atlanta

30342

St. Joseph's Hospital / Atlanta, Atlanta

33606

Tampa General Hospital, Tampa

35610

Shands Hospital at University of Florida, Gainesville

40202

Jewish Hospital, Louisville

43210

Ohio State University Medical Center, Columbus

43214

Riverside Methodist Hospital, Columbus

44109

The Metro Health System, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

46260

St. Vincent's Hospitals and Health Services, Indianapolis

48197

Michigan Heart, Ypsilanti

48202

Henry Ford Hospital, Detroit

53233

St. Luke's Medical Center, Milwaukee

55407

Minneapolis Heart Institute Foundation, Minneapolis

55455

University of Minnesota Medical Center, Minneapolis

55905

Mayo Clinic Rochester, Rochester

58122

Sanford Medical Center, Fargo

60453

Advocate Christ Medical Center, Oak Lawn

60637

University of Chicago Medical Center, Chicago

63110

Barnes Jewish Hospital, St Louis

64111

St. Luke's Hospital of Kansas City, Kansas City

72205

Baptist Medical Center, Little Rock

73112

INTEGRIS Baptist Medical Center, Inc., Oklahoma City

74104

St. John Medical Center, Tulsa

75226

Baylor University Medical Center, Dallas

77030

Memorial Hermann, TMC, Houston

Methodist Hospital, Houston

Texas Heart Institute, Houston

84132

University of Utah Medical School, Salt Lake City

87102

New Mexico Heart Institute, Albuquerque

90033

Keck Medical Center of USC, Los Angeles

90211

Cedars Sinai Medical Center, Beverly Hills

92123

Sharp Memorial Hospital, San Diego

94305

Stanford University, Stanford

97239

Oregon Health and Science University, Portland

98195

University of Washington Medical Center, Seattle

06510

Yale New Haven Hospital, New Haven

07112

Newark Beth Israel Medical Center, Newark

08691

Mercer Bucks Cardiology, Robbinsville

Sponsors
All Listed Sponsors
collaborator

Thoratec Corporation

INDUSTRY

lead

Abbott Medical Devices

INDUSTRY

NCT01452802 - Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management | Biotech Hunter | Biotech Hunter